Boundless Bio will present at the Guggenheim Biotech Summit on February 12, discussing innovations in cancer treatments.
Quiver AI Summary
Boundless Bio, a clinical-stage oncology company focused on treating cancers with oncogene amplification via extrachromosomal DNA (ecDNA), announced that CEO Zachary Hornby will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12 in New York. The session will provide insights into the company's mission to develop transformative therapies, particularly their candidate BBI-940, a novel ecDNA-targeted treatment. A live and archived webcast of the chat will be available on Boundless Bio's website. The company is based in San Diego, CA, and aims to address the needs of cancer patients affected by ecDNA-related oncogene amplification.
Potential Positives
- Boundless Bio is participating in a prominent industry event, the Guggenheim Emerging Outlook: Biotech Summit 2026, which provides visibility and potential networking opportunities.
- The participation of the CEO in a fireside chat highlights the company's leadership and innovation in oncology, potentially attracting investor interest.
- Boundless Bio is focused on addressing a significant unmet need in cancer therapeutics, specifically targeting oncogene amplified tumors, which underscores its commitment to advancing cancer treatment.
- The development of BBI-940 as a potentially first-in-class therapeutic candidate positions the company favorably within the competitive oncology landscape.
Potential Negatives
- e
FAQ
What is the purpose of Boundless Bio's participation in the Guggenheim Emerging Outlook: Biotech Summit 2026?
Boundless Bio aims to share insights on its innovative approaches to treating oncogene amplified cancers.
When is the fireside chat at the Guggenheim Summit?
The fireside chat is scheduled for February 12, 2026, at 3:00 p.m. ET.
How can I access the live webcast of the fireside chat?
The live and archived webcast will be available under “Events & Presentations” on Boundless Bio’s website.
What is the focus of Boundless Bio's research?
Boundless Bio focuses on extrachromosomal DNA (ecDNA) biology to address oncogene amplified cancers.
What is BBI-940, developed by Boundless Bio?
BBI-940 is a potentially first-in-class oral selective Kinesin degrader aimed at targeting ecDNA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BOLD Hedge Fund Activity
We have seen 9 institutional investors add shares of $BOLD stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REDMILE GROUP, LLC removed 343,576 shares (-58.3%) from their portfolio in Q3 2025, for an estimated $422,598
- STONEPINE CAPITAL MANAGEMENT, LLC added 307,278 shares (+289.4%) to their portfolio in Q3 2025, for an estimated $377,951
- ALMITAS CAPITAL LLC removed 148,697 shares (-63.1%) from their portfolio in Q3 2025, for an estimated $182,897
- RENAISSANCE TECHNOLOGIES LLC added 102,562 shares (+84.8%) to their portfolio in Q3 2025, for an estimated $126,151
- VANGUARD GROUP INC added 93,100 shares (+16.3%) to their portfolio in Q4 2025, for an estimated $111,720
- GOLDMAN SACHS GROUP INC removed 56,005 shares (-79.7%) from their portfolio in Q3 2025, for an estimated $68,886
- Y-INTERCEPT (HONG KONG) LTD removed 55,242 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $67,947
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BOLD Analyst Ratings
Wall Street analysts have issued reports on $BOLD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/11/2025
To track analyst ratings and price targets for $BOLD, check out Quiver Quantitative's $BOLD forecast page.
Full Release
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026.
The fireside chat session is scheduled for Thursday, February 12, in New York, NY, at 3:00 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com and follow us on LinkedIn and X .
Contacts:
James Lee, Boundless Bio
[email protected]
Investors
Renee Leck
[email protected]
